logo-loader
viewDyadic International Inc

Dyadic working with global research partners to express potential coronavirus vaccines using C1

Dyadic International Inc (NASDAQ:DYAI) CEO Mark Emalfarb tells Proactive the Florida-based biotech is 'delivering on its promises.' Emalfarb says it saw a busy first quarter where the company stepped up in the global fight against the coronavirus pandemic.

Emalfarb says among its recent achievements, the company is working with worldwide research partners to leverage its proprietary C1 technology to express an increasing number of potential coronavirus vaccines and antibody candidates.

Quick facts: Dyadic International Inc

Price: 8.46 USD

NASDAQ:DYAI
Market: NASDAQ
Market Cap: $232.39 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Dyadic International Inc named herein, including the promotion by the Company of Dyadic International Inc in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Dyadic paves the way for patients to gain access to low-cost...

Dyadic (NASDAQ) President and CEO Mark Emalfarb joined Steve Darling from Proactive Vancouver with news the company continues to very busy even with the COVID-19 crisis. Emalfarb discussing what the company is doing with other partners to help battle the virus.  Emalfarb also telling...

on 04/01/2020

2 min read